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TRANSPLANTATION
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Children with sickle cell disease experience organ damage, impaired quality of life, and
premature mortality. Allogeneic bone marrow transplant from an HLA-matched sibling
can halt disease progression but is limited by donor availability. A Blood and Marrow
• Children with sickle cell
Transplant Clinical Trials Network (BMT CTN) phase 2 trial conducted from 2008 to 2014
disease engrafted unrelated
enrolled 30 children aged 4 to 19 years; 29 were eligible for evaluation. The primary
donor marrow after reduced
objective was 1-year event-free survival (EFS) after HLA allele-matched (at HLA-A, -B,
intensity conditioning.
-C, and -DRB1 loci) unrelated donor transplant. The conditioning regimen included
• A high incidence of GVHD
alemtuzumab, fludarabine, and melphalan. Graft-versus-host disease (GVHD) prophyand associated mortality
laxis included calcineurin inhibitor, short-course methotrexate, and methylprednisolone.
compromised safety of the
Transplant indications included stroke (n 5 12), transcranial Doppler velocity >200 cm/s
trial.
(n 5 2), ‡3 vaso-occlusive pain crises per year (n 5 12), or ‡2 acute chest syndrome
episodes (n 5 4) in the 2 years preceding enrollment. Median follow-up was 26 months
(range, 12-62 months); graft rejection was 10%. The 1- and 2-year EFS rates were 76% and 69%, respectively. The corresponding rates
for overall survival were 86% and 79%. The day 100 incidence rate of grade II-IV acute GVHD was 28%, and the 1-year incidence rate of
chronic GVHD was 62%; 38% classified as extensive. There were 7 GVHD-related deaths. A 34% incidence of posterior reversible
encephalopathy syndrome was noted in the first 6 months. Although the 1-year EFS met the prespecified target of ‡75%, this regimen
cannot be considered sufficiently safe for widespread adoption without modifications to achieve more effective GVHD prophylaxis.
The BMT CTN #0601 trial was registered at www.clinicaltrials.gov as #NCT00745420. (Blood. 2016;128(21):2561-2567)

Key Points

Introduction
Sickle cell disease (SCD) is a monogenic hemoglobin disorder
characterized by hemolytic anemia with variable clinical manifestations
after endothelial damage and vasculopathy.1 Hypoperfusion results in
multiple organ damage. In patients with severe disease, symptoms
manifest early and progress during childhood. Allogeneic hematopoietic cell transplantation can replace sickle erythropoiesis. The results of
HLA-matched sibling donor transplants are excellent, with event-free
survival (EFS) in excess of 90% and with acceptable rates of graft

rejection (GR) and graft-versus-host disease (GVHD).2-5 HLAmatched sibling donor transplants account for the majority of
transplants performed worldwide for hemoglobinopathy.6,7 However, only 18% of patients with SCD have an HLA-matched sibling
donor in the United States.8 HLA-matched adult unrelated donors
(URDs) have been used to expand the donor pool for nonmalignant
hematologic disorders, but their role in SCD transplants is
unclear.9-11 Although the likelihood of ﬁnding an HLA-matched
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URD for African Americans is low at 16% to 19%, utilization of
these donors does expand the donor pool.12 To date, most SCD
transplants have used myeloablative conditioning regimens, but
these can result in toxicities such as growth inhibition, gonadal
hypofunction, and sterility.13-16 Reduced-intensity conditioning
(RIC) regimens, although associated with a more favorable toxicity
proﬁle, can be associated with higher rates of GR, especially with
graft sources such as umbilical cord blood.17-20 A RIC regimen
augmented with host immunoablation by alemtuzumab was previously successful in achieving donor engraftment.21,22 In that report
of HLA-matched sibling donor bone marrow transplant (BMT) in 52
children with hemoglobinopathies, acute and chronic GVHD rates
were 23% and 13%, respectively.21 The regimen was adopted for a
phase 2 URD transplant trial with bone marrow or umbilical cord
blood grafts through the Blood and Marrow Transplant Clinical
Trials Network (BMT CTN #0601; NCT 00745420). This report
describes outcomes from the trial using bone marrow grafts. The
umbilical cord blood arm was closed early after a high GR rate.19

Table 1. Treatment regimen
Day
223

Treatment
Alemtuzumab test dose 3 mg IV*

222

Alemtuzumab 10 mg IV†

221

Alemtuzumab 15 mg IV†

220

Alemtuzumab 20 mg IV†

28

Fludarabine 30 mg/m2 IV

27

Fludarabine 30 mg/m2 IV

26

Fludarabine 30 mg/m2 IV

25

Fludarabine 30 mg/m2 IV

24

Fludarabine 30 mg/m2 IV

23

Melphalan 140 mg/m2 IV; cyclosporine or
tacrolimus dosed to maintain appropriate levels
through day 100, and then tapered to day 180

22

Rest

21

Rest

0

Bone marrow infusion

1

Methotrexate 7.5 mg/m2 IV

3

Methotrexate 7.5 mg/m2 IV

6

Methotrexate 7.5 mg/m2 IV

7

Methylprednisolone 1 mg/kg per day IV through
day 28, and then taper granulocyte colonystimulating factor 5 mg/kg body weight per day
IV until absolute neutrophil count is $0.5 3 109/L

Methods

for 3 consecutive days

Study design
The primary end point was 1-year EFS; death from any cause, GR, or recurrent
disease was considered an event. Prespeciﬁed secondary end points included
overall survival, hematopoietic recovery, acute and chronic GVHD, infections,
hepatic sinusoidal syndrome, interstitial pneumonitis, seizure, posterior reversible encephalopathy syndrome (PRES), and health-related quality of life
(HRQL). The trial opened on 11 April 2008 and closed to enrollment on 24 April
2014. Enrollment was paused once for clariﬁcation of HLA typing requirements
once (for 6 months) during this period. This analysis includes data collected as of
March 2016. The median follow-up of surviving patients was 26 months (range,
12-62 months). All patients were followed for at least 24 months, except for
1 patient who was lost to follow-up at 12 months.

*The test dose of alemtuzumab was administered 24 hours before the first dose,
shown in this example on day 223.
†Alemtuzumab treatment was required to be administered on 3 consecutive
days but could begin on day 222, 221, or 220 and end on day 220, 219, or 218,
respectively.

transfusions for .1 year. Hemoglobin S level was maintained at #45% within
7 days of initiation of transplant conditioning, and chelation and/or hydroxyurea
were discontinued 48 hours before initiation of conditioning. Ineligible patients
included those with an HLA-matched sibling, HIV seropositivity, a performance
score ,40, and uncontrolled bacterial, viral, or fungal infection.
Treatment

Patients
The protocol was approved by the institutional review board at each of the
participating institutions. Informed consent was obtained from parents or from
patients aged .18 years, and assent was obtained from patients aged 7-18 years
before enrollment. The consent form extensively described alternate conservative
treatment approaches for SCD, as well as the pros and cons of transplant. Trial
eligibility was conﬁrmed by 3 independent hematologists. Eligible patients were
aged 3.0 to 20 years who had severe SCD indicated by 1 or more the following:
(1) clinically signiﬁcant neurologic event (stroke) or any neurologic defect lasting
.24 hours and accompanied by an infarct on cerebral magnetic resonance
imaging; (2) a transcranial Doppler velocity .200 cm/s by the nonimaging
technique, or velocity that exceeded 185 cm/s by the imaging technique
measured at a minimum of 2 separate occasions 1 month or more apart23; (3) a
minimum of 2 episodes of acute chest syndrome within the preceding 2-year
period and deﬁned as new pulmonary alveolar consolidation involving at least 1
complete lung segment despite adequate supportive care measures; and (4)
minimum of 3 new pain events per year in the previous 2 years and deﬁned as
new onset of pain lasting for at least 2 hours, for which there was no other
explanation, and occurred despite adequate supportive care measures. Adequate
organ function pretransplant required the following: serum creatinine levels ,1.5
times the upper limit of normal for age and the glomerular ﬁltration rate
.100 mL/min per 1.73 m2 or adjusted for age; alanine aminotransferase and
aspartate aminotransferase ,5 times the upper limit of normal and direct serum
bilirubin ,2 times the upper limit of normal; left ventricular ejection fraction .40%
or left ventricular shortening fraction .26%; and diffusing capacity of the lungs for
carbon monoxide .40% of predicted (corrected for hemoglobin). Patients with
serum ferritin .1000 ng/mL were required to have a liver biopsy demonstrating the
absence of cirrhosis and bridging ﬁbrosis if they had received regular red cell

The conditioning regimen included alemtuzumab, ﬂudarabine, and melphalan,
with the alemtuzumab administered between day 22 and day 18 before graft
infusion to achieve host immunoablation (Table 1). Prophylaxis for GVHD
consisted of a calcineurin inhibitor (tacrolimus or cyclosporine) administered
from day 23 through day 100 after graft infusion, with subsequent taper through
day 180; methotrexate 7.5 mg/m2 on days 1, 3, and 6; and methylprednisolone
1 mg/kg per day from days 7 through 28, with subsequent taper by 20% per week.
Supportive care recommendations included granulocyte colony-stimulating
factor commenced on day 7 and continued until an absolute neutrophil count of
1.5 3 109/L on 3 days after the nadir, weekly surveillance for cytomegalovirus
and Epstein-Barr virus reactivation, seizure prophylaxis for the duration of use of
calcineurin inhibitors, strict blood pressure control, preemptive therapy for viral
infections, bacterial prophylaxis through day 100, and prompt treatment of overt
or suspected infections. To mitigate the risk of intracranial hemorrhage, platelet
count was maintained at $50 3 109/L.24
Outcomes
The primary end point was 1-year EFS. Primary or secondary GR or death was
considered an event. Primary GR was deﬁned as the presence of ,20% donor
cells as assessed by bone marrow or peripheral blood chimerism assays (any
lineage) on or after day 42. Secondary GR was deﬁned as the presence of ,20%
donor-derived hematopoietic cells in peripheral blood or bone marrow in a
patient with prior evidence of .20% donor cells. The level was chosen based on
absence of SCD symptoms, even when donor chimerism in blood or marrow
approached 10%.21,25 Survival was deﬁned as the time from transplant to death or
last follow-up. Neutrophil recovery was deﬁned as the ﬁrst of 3 days when the
absolute neutrophil count was $0.5 3 109/L. Platelet recovery was deﬁned as the
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ﬁrst of 7 days without a platelet transfusion that the platelet count was $50 3109/L.
Acute and chronic GVHD were graded by Seattle (ie, limited/extensive) and
National Institutes of Health criteria (ie, mild/moderate/severe).26 Common
Terminology Criteria for Adverse Events version 3.0 was used to report expected
grade 3-5 adverse events. Major regimen-related toxicity (RRT) was deﬁned as
grade 4 or 5 in any organ system or grade 3 for pulmonary, cardiac, renal, central
nervous system, oral, or mucosal.27 HRQL was assessed pretransplant (within
2 months of transplant), and thereafter on day 100, at 6 months, and at 1 year
posttransplant using the Child Health Questionnaire (CHQ). The CHQ was chosen
because it was the only HRQL measure that was validated and reliable for use in
children with SCD at the time the study commenced.28,29 The CHQ-Parent Form
50 was used for parent reports, and the CHQ-Child Form 87 was used for the child
self-report for children aged $10 years.

UNRELATED DONOR TRANSPLANT FOR SICKLE CELL DISEASE

Table 2. Donor, recipient, and transplant characteristics
Characteristics

The primary hypothesis was that a RIC regimen would be sufﬁcient for stable
engraftment after HLA-matched URD BMT and result in 1-year EFS $75%.
The sample size of 30 patients was chosen based on a 95% conﬁdence interval
(CI) length of 31. However, 1 patient was deemed ineligible after enrollment
because the patient and donor were mismatched at 2 HLA-loci. Therefore the
analysis includes 29 patients.
EFS and overall survival were calculated using the Kaplan-Meier
estimator.30 The cumulative incidence method was used to estimate the
incidence of events in the presence of competing risks for neutrophil and
platelet recovery and acute and chronic GVHD; in each case, death was
considered the competing risk.31 HRQL measurement was based on the
CHQ Parent Form 50 (for patients 5-18 years old) and the CHQ Child Form
87 (for patients 10-18 years old). Mean scores for the CHQ were calculated
based on a 4- to 6-point response scale for each item and transformed
according to the developer’s instructions to a 0 to 100 scale, with a higher
score representing a better quality of life.32 One domain, Change in Health,
is composed of 1 question that is reported on a 1- to 5-point scale, with a
higher number meaning better health. The impact of a change by .1 point is
considered signiﬁcant on a 5-category scale.33,34 HRQL data were analyzed
for changes in mean HRQL score from pretransplant measurement and
performed as an exploratory analysis, given the small sample size. A
paired Student t test was used to assess changes from baseline to each
posttransplant time point (day 100, 6 months, and 1 year). Only P values
of ,.01 were considered signiﬁcant for the HRQL analyses, given the
multiple comparisons. All analyses were performed using SAS version 9.3
(Cary, NC).

Results
Patient and donor characteristics

The characteristics of the donors and 29 patients who met eligibility
criteria are shown in Table 2. All patients had a hemoglobin SS
genotype. The median age at transplant was 14 years (range, 6-19
range), and 55% were male. Indications for transplant included
stroke (41%), elevated transcranial Doppler velocity (7%), recurrent episodes of acute chest syndrome (14%), or signiﬁcant pain
(41%). Pretransplant, 26 patients had performance scores of 90 or
100, 2 patients had a score of 80, and the remaining patient had a
score of 70. All patients had received erythrocyte transfusions
before transplant. The median serum ferritin level was 722 ng/mL
(range, 55-7324 ng/mL). Eight patients underwent liver biopsy for
history of chronic red cell transfusions and a serum ferritin level of
.1000 ng/mL, but no patient was excluded because none had
evidence of bridging ﬁbrosis or liver cirrhosis. The median
hemoglobin S at transplant was 20.8% (range, 3.9%-43%). All 29
eligible patients received bone marrow grafts from an adult URD
and were HLA matched at the allele-level at HLA-A, -B, -C, and

n

Donor*
Race/ethnicity
White

11

African American

11

Multiracial

5

Not reported

2

Recipient†
Sex
Male

16

Female

13

Race/ethnicity
African American

Statistical analysis

2563

Hispanic

26
3

Indications for transplant‡
Stroke
Transcranial Doppler velocity .200 cm/s
Acute chest syndrome
Vaso-occlusive pain crisis
Chronic blood transfusion before transplant

12
2
4
12
14

Performance score
100

17

90

9

80

2

70

1

Transplant
CMV-seronegative donor and recipient

8

CMV-seropositive donor and recipient

9

CMV-seronegative donor and CMV-seropositive

3

recipient
CMV-seropositive donor and CMV-seronegative

9

recipient
ABO blood group matched
ABO blood group major mismatch
ABO blood group minor mismatch
Sex-matched transplants

15
9
5
15

Female donor, male recipient

7

Male donor, female recipient

7

CMV, cytomegalovirus.
*Median donor age was 35 years (range, 21-55 years).
†Median recipient age was 14 years (range, 6-19 years).
‡Some patients had more than 1 indication.

-DRB1. One unrelated adult donor was a carrier with hemoglobin
AS genotype. The median total nucleated cell dose of the bone
marrow graft was 3.5 3 108/kg (range, 1.3 3 108/kg to 6.8 3 108/kg).
The median CD34 dose of the graft was 2.9 3 106/kg (range, 0.3 3
106/kg to 9.2 3 106/kg).
EFS, overall survival, and engraftment

The primary end point was met. The 1-year EFS was 76% (95% CI,
56-88) and the 1-year overall survival was 86% (95% CI, 67-95). At
data cutoff in March 2016, the 2-year EFS was 69% (95% CI, 48-82)
and the 2-year overall survival was 79% (95% CI, 59-90) (Figure 1).
Twenty-seven of 29 patients engrafted. The median time to neutrophil
recovery was 12 days (range, 6-16 days) and the median time to platelet
recovery was 24 days (range, 7-90 days), similar to published results
using URDs.35 Two patients experienced primary GR (day 39 and
day 91); 1 patient developed secondary GR on day 48 for a
cumulative incidence of GR of 10%. All 3 patients experiencing
GR recovered host hematopoiesis without marrow aplasia. Because
mixed chimerism occurs frequently after transplant for SCD, we
evaluated the percentage of donor cells at 3 months, at 1 year, and at
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3
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N at risk 29
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6

9
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Figure 1. Probability of EFS and overall survival. The 2-year probability of EFS (A) and overall survival (B) after URD transplant for severe SCD.

2 years.20,21,25 All engrafted patients demonstrated .90% donor
chimerism at 3 months, and this persisted at the 1-year and 2-year
time points in evaluable patients (n 5 22 and n 5 19 at 1 and 2
years, respectively). Hemoglobin S levels were undetectable in all
but 1 patient who received a graft from an URD with sickle cell trait,
and the hemoglobin S level was consequently 42%.
Although a RIC regimen was administered, RRT was implicated
in 83% of grade 3-5 adverse events (63/76). Ten patients developed
PRES with a 1-year incidence of 34% (95% CI, 18-52), resulting
in reiteration of the importance of strict blood pressure control based
on lower blood pressure norms established for SCD patients and
of correcting any electrolyte imbalance. Two PRES events occurred before transplant. In the remaining 8 patients, calcineurin
inhibitor was withdrawn. Thereafter, 1 patient received sirolimus,
2 received mycophenolate mofetil, and 5 received no alternate
GVHD prophylaxis. Three patients developed renal failure and
required dialysis. These events were transient, and all patients
fully recovered.

Table 3. Cause of death in 7 patients
Patient age, y Time of death, d

Complications at the time of death

17

231

Acute GVHD (gut); opportunistic infection;

16

539

Chronic GVHD; CMV infection;

ARDS
encephalomyelitis; cardiorespiratory failure
17

200

Acute GVHD (gut); respiratory and renal failure

19

960

Chronic GVHD

16

507

Chronic GVHD; VRE and HSV infections

14

199

Acute GVHD; Candida and CMV infections;

18

143

Acute GVHD (gut); pulmonary hemorrhage;

respiratory and renal failure
Staphylococcus aureus pneumonia
ARDS, acute respiratory distress syndrome; CMV, cytomegalovirus; HSV,
herpes simplex virus; VRE, vancomycin-resistant Enterococcus.

Eight patients died after transplant. Seven patients, all aged $14
years, died of GVHD and related complications (Table 3). Five of
the 7 patients had ferritin levels .1000 ng/mL, although none had
ﬁbrosis or cirrhosis. One patient with primary GR died of infection
3 months after a second myeloablative transplant. Four GVHDrelated deaths occurred within the ﬁrst year after transplant,
whereas 3 occurred between 507 and 960 days.
GVHD

The cumulative incidence on day 100 of grade II-IV acute GVHD was
28% (95% CI, 13-45), and was 17% (95% CI, 6-33) for grade III-IV
acute GVHD (Figure 2A). The cumulative incidence of chronic GVHD
at 1 year (Figure 2B) was 62% (95% CI, 41-77), with 38% classiﬁed as
extensive. By National Institutes of Health scoring criteria, chronic
GVHD was classiﬁed as mild in 6 patients, moderate in 8, and severe in
5. Of the 19 patients with sustained donor engraftment, 4 discontinued
immune suppression by 1 year, 6 discontinued in the second year, and 5
discontinued after 2 years. Of the remaining 4 patients, 1 was weaning
immune suppression when lost to follow-up at 1 year, 2 were weaning
post-GVHD resolution, and 1 continued treatment of stable chronic
GVHD. Performance scores at the 2-year or last follow-up visit were 100
in 13 patients, 90 in 5 patients, and 80 in 3 patients.
HRQL

SCD adversely affects quality of life, as previously reported.36 We were
interested in learning whether HRQL improved after URD BMT in
pediatric recipients. Validated measures for HRQL include change
in health, physical functioning, behavior, and self-esteem. Parental
proxies and patients who completed the forms, as indicated based on
age, reported signiﬁcant improvements in the change in health domain
posttransplant (Table 4). Although initially, patients did not report
any differences, parent proxies (n 5 21) reported signiﬁcantly worse
Self-Esteem HRQL scores (mean change, 215.12; P 5 .006) but
signiﬁcantly better General Health Perception scores (mean change,
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Figure 2. Probability of GVHD. The 100-day probability of acute GVHD (A) and the 1-year probability of GVHD (B) after URD transplant for severe SCD.

ﬂudarabine was used to overcome the higher risk of GR with URD
BMT while limiting the toxicities associated with myeloablative
regimens that may be exacerbated in patients with severe SCD and may
limit patient acceptance.14,16,39,40
Although the trial met the prespeciﬁed 1-year end point of 75%
EFS, the 1-year chronic GVHD rate was higher than expected after
HLA-matched URD BMT, and GVHD was the predominant cause of
death, noted primarily in older patients. Reports in African Americans
with severe aplastic anemia (combining sibling and URD transplants)
suggest an overall chronic GVHD rate of 36% (95% CI, 24-48)
compared with 30% noted in whites (P 5 .36), although extensive
chronic GVHD was observed more commonly in African Americans
than in whites (72% vs 49%; P 5 .06), as was GVHD-related
mortality.41 Other than race, additional factors may have inﬂuenced the
observed high rates of chronic GVHD in this trial. HLA matching at
HLA-DPB1 loci was not considered in donor selection, and a mismatch
at this locus increases the risk of acute GVHD.42-44 Another plausible
explanation could be the timing of alemtuzumab administration
3 weeks before infusion of the graft (distal administration) to overcome
host rejection of the graft. It was timed to achieve low alemtuzumab

11.13; P 5 .0003) at day 100 compared with pretransplant baseline.
The child-reported Change in Health score (n 5 13) improved by a
mean of 1.46 (P 5 .0013) at 12 months posttransplant compared with
pretransplant scores. Parental proxies reported similar improvements at
6 and 12 months compared with pretransplant scores (mean change,
1.15 and 1.53, respectively; P , .01). The limited sample size
precluded subanalyses such as assessing these changes in patients with
and without chronic GVHD (see supplemental Table 1, available on the
Blood Web site).

Discussion
Although EFS after HLA-matched sibling donor transplant is .90%,
most patients do not have an HLA-matched sibling.4,5,21,37,38 This is the
ﬁrst multicenter URD transplant trial for SCD in North America and
was conducted to expand access to transplantation utilizing HLAmatched URDs. The RIC regimen of alemtuzumab, melphalan, and

Table 4. HRQL changes from pretransplant baseline to day 100, 6 months, and 1 year
Day 100
HRQL score

6 Months

1 Year

n

Mean (SEM)

P

n

Mean (SEM)

P

n

Mean (SEM)*

P

Self-Esteem

21

215.12 (4.89)

.0057*

20

211.46 (6.28)

.0839

15

23.61 (6.66)

.5959

General Health Perception

21

11.13 (2.51)

.0003*

20

7.63 (3.31)

.0326

15

8.89 (5.27)

.1135

Change in Health

21

0.90 (0.38)

.0286

20

1.15 (0.36)

.0052*

15

1.53 (0.48)

.0062*

Self-Esteem

18

20.59 (4.51)

.8976

16

24.33 (5.87)

.4722

13

4.97 (5.33)

.3691

General Health Perception

18

21.90 (4.29)

.6631

16

26.69 (4.99)

.2001

13

6.99 (6.35)

.2927

Change in Health

18

0.33 (0.45)

.4691

16

0.19 (0.52)

.7225

13

1.46 (0.35)

.0013*

Parent proxy

Child

Negative mean change denotes worsening HRQL score; positive mean change denotes improved HRQL score. Other items tested include the following (none of which
reached the level of significance at any of the time points tested): physical functioning; social limitations due to emotional difficulties; social limitations due to behavioral
difficulties; social limitations due to physical health; bodily pain and discomfort; behavioral; mental health; emotional impact; time impact; family activities; global health; global
behavior; change in health; family cohesion; physical summary; and psychosocial summary.
SEM, standard error of the mean.
*P values ,.01 are statistically significant.
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levels at the time of graft infusion to maximize donor T-cell engraftment,
and thus did not have a signiﬁcant effect as a GVHD prophylaxis
agent.21 Chronic GVHD rates are also expected to be higher in URD
BMT and increase with recipient age; the higher rates observed in this
trial are consistent with less protection against chronic GVHD.45-47
Further, the protocol recommended calcineurin inhibitor taper early
(after day 100) in the absence of GVHD and may have contributed to
de novo chronic GVHD subsequently. Chronic GVHD developed in
8 of 10 patients after they developed PRES symptoms. The protocol
did not specify alternate GVHD prophylaxis in the event of PRES,
and treatment was left to the center’s choice. Because it is common
practice to discontinue or modify calcineurin inhibitor use after
PRES, it is possible that the withdrawal or modiﬁcation of the
calcineurin inhibitor after the development of PRES may have
additionally contributed to GVHD. Alemtuzumab or anti-human
T-lymphocyte immune globulin used just proximal to transplant can offer
better protection against GVHD but predisposes to mixed chimerism and
rejection.48-50 Novel preparative agents such as treosulfan and GVHD
prophylaxis methods such as posttransplant cyclophosphamide have
shown recent promise in transplantation for SCD.51,52
HRQL improved signiﬁcantly by 1 year posttransplant in the areas
of Change in Health for these patients compared with pretransplant
scores. Other HRQL domains did not show signiﬁcant changes from
baseline. The signiﬁcant changes noted here, even in this small sample
size, support that these children felt better and reported better
functioning overall related to their health after transplant, despite the
high incidence of chronic GVHD. We would expect patients with
signiﬁcant chronic GVHD after BMT to experience lower HRQL than
those without, but the sample size was too small for a meaningful
comparison between the two groups.
No patient developed hepatic sinusoidal syndrome or idiopathic
pulmonary syndrome. However, one-third of the patients developed
PRES (a known complication of SCD and hemoglobinopathy
transplants) that was reversible, despite our recommendation for strict
blood pressure monitoring and prompt intervention.53,54 Baseline
blood pressure in SCD patients is generally lower than published norms
for age, race, and sex, and the use of corticosteroid and calcineurin
inhibitors may have exacerbated this complication. 53,55-57
In conclusion, the trial met its prespeciﬁed 1-year EFS, and
signiﬁcantly improved HRQL was reported posttransplant. However,
although the RIC provided successful engraftment in the majority of
patients, the regimen cannot be considered safe for widespread
adoption without modiﬁcation due to the RRT and high rate of chronic

GVHD, which was the predominant cause of mortality. Future trials on
URD transplantation for SCD should focus on strategies that minimize
risks of GVHD and include stopping rules for chronic GVHD.
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